Cargando…

Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST)

BACKGROUND: The renin‐angiotensin‐aldosterone system (RAAS), when chronically activated, is harmful and RAAS‐suppressive drugs are beneficial in the treatment of congestive heart failure (CHF). Mineralocorticoid receptor antagonists are widely used in the treatment of CHF in people. HYPOTHESIS/OBJEC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coffman, Melissa, Guillot, Emilie, Blondel, Thomas, Garelli‐Paar, Catherine, Feng, Shuo, Heartsill, Susanne, Atkins, Clarke E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	SMALL ANIMAL
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295662/ https://www.ncbi.nlm.nih.gov/pubmed/34028078 http://dx.doi.org/10.1111/jvim.16155

Ejemplares similares

Effect of spironolactone and benazepril on furosemide‐induced diuresis and renin‐angiotensin‐aldosterone system activation in normal dogs
por: Adin, Darcy, et al.
Publicado: (2021)

Efficacy of oral torasemide in dogs with degenerative mitral valve disease and new onset congestive heart failure: The CARPODIEM study
por: Besche, Beatrice, et al.
Publicado: (2020)

Comparison of Efficacy of Long‐term Oral Treatment with Telmisartan and Benazepril in Cats with Chronic Kidney Disease
por: Sent, U., et al.
Publicado: (2015)

Evaluation of benazepril in cats with heart disease in a prospective, randomized, blinded, placebo‐controlled clinical trial
por: King, Jonathan N., et al.
Publicado: (2019)

Radiographic lung congestion scores in dogs with acute congestive heart failure caused by myxomatous mitral valve disease
por: Koster, Liza, et al.
Publicado: (2023)

Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo‐Controlled Clinical Trial
por: King, J.N., et al.
Publicado: (2017)

Long‐term Outcome of Irish Wolfhound Dogs with Preclinical Cardiomyopathy, Atrial Fibrillation, or Both Treated with Pimobendan, Benazepril Hydrochloride, or Methyldigoxin Monotherapy
por: Vollmar, A.C., et al.
Publicado: (2016)

Cardiorenal and endocrine effects of synthetic canine BNP1‐32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease
por: Yata, Mariko, et al.
Publicado: (2019)

Serum Concentrations of Leptin and Adiponectin in Dogs with Myxomatous Mitral Valve Disease
por: Kim, H.‐S., et al.
Publicado: (2016)

The Mitral INsufficiency Echocardiographic score: A severity classification of myxomatous mitral valve disease in dogs
por: Vezzosi, Tommaso, et al.
Publicado: (2021)

Effect of prespecified therapy escalation on plasma NT‐proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease
por: Hezzell, Melanie J., et al.
Publicado: (2018)

Atrial Fibrillation as a Prognostic Indicator in Medium to Large‐Sized Dogs with Myxomatous Mitral Valvular Degeneration and Congestive Heart Failure
por: Jung, S.W., et al.
Publicado: (2016)

Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs
por: Nakamura, K., et al.
Publicado: (2017)

Prevalence and risk factors for atrial fibrillation in dogs with myxomatous mitral valve disease
por: Guglielmini, Carlo, et al.
Publicado: (2020)

Radiographic quantification of left atrial size in dogs with myxomatous mitral valve disease
por: Lam, Christopher, et al.
Publicado: (2021)

Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease
por: McManamey, Anna K., et al.
Publicado: (2023)

Echocardiographic Estimates of Right Ventricular Systolic Function in Dogs with Myxomatous Mitral Valve Disease
por: Chapel, E.H., et al.
Publicado: (2017)

Echocardiographic predictors of first onset of atrial fibrillation in dogs with myxomatous mitral valve disease
por: Baron Toaldo, Marco, et al.
Publicado: (2020)

Peripheral blood lymphocyte subtypes in dogs with different stages of myxomatous mitral valve disease
por: Druzhaeva, Natalia, et al.
Publicado: (2021)

Echocardiographic estimation of left ventricular‐arterial coupling in dogs with myxomatous mitral valve disease
por: Osuga, Tatsuyuki, et al.
Publicado: (2021)

Prognostic value of serum cystatin C concentration in dogs with myxomatous mitral valve disease
por: Iwasa, Naoki, et al.
Publicado: (2023)

Reproducibility of echocardiographic indices of left atrial size in dogs with subclinical myxomatous mitral valve disease
por: Hsue, Weihow, et al.
Publicado: (2020)

Diagnostic Value of Selected Echocardiographic Variables to Identify Pulmonary Hypertension in Dogs with Myxomatous Mitral Valve Disease
por: Tidholm, A., et al.
Publicado: (2015)

Prognostic value of echocardiographic indices of left atrial morphology and function in dogs with myxomatous mitral valve disease
por: Baron Toaldo, Marco, et al.
Publicado: (2018)

Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study
por: Boswood, Adrian, et al.
Publicado: (2020)

Utility of radiographic measurements to predict echocardiographic left heart enlargement in dogs with preclinical myxomatous mitral valve disease
por: Poad, Megan H., et al.
Publicado: (2020)

Prognostic value of left ventricular‐arterial coupling estimated using echocardiography in dogs with myxomatous mitral valve disease
por: Osuga, Tatsuyuki, et al.
Publicado: (2021)

Prognostic value of pulmonary vascular resistance estimated by echocardiography in dogs with myxomatous mitral valve disease and pulmonary hypertension
por: Yuchi, Yunosuke, et al.
Publicado: (2023)

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study—A Randomized Clinical Trial
por: Boswood, A., et al.
Publicado: (2016)

Real‐Time 3‐Dimensional Echocardiographic Assessment of Effective Regurgitant Orifice Area in Dogs With Myxomatous Mitral Valve Disease
por: Tidholm, A., et al.
Publicado: (2017)

Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration
por: Reimann, M.J., et al.
Publicado: (2017)

Polymorphisms in the serotonin transporter gene and circulating concentrations of neurotransmitters in Cavalier King Charles Spaniels with myxomatous mitral valve disease
por: Reimann, Maria J., et al.
Publicado: (2021)

Microwave-assisted Synthesis of an Important Intermediate of Benazepril
por: Mistry, B, et al.
Publicado: (2010)

Evaluation of urinary neutrophil gelatinase‐associated lipocalin to detect renal tubular damage in dogs with stable myxomatous mitral valve disease
por: Troia, Roberta, et al.
Publicado: (2022)

Prognostic Value of Right Ventricular Tei Index in Dogs with Myxomatous Mitral Valvular Heart Disease
por: Nakamura, K., et al.
Publicado: (2016)

Assessment of Left Atrial Deformation and Function by 2‐Dimensional Speckle Tracking Echocardiography in Healthy Dogs and Dogs With Myxomatous Mitral Valve Disease
por: Baron Toaldo, M., et al.
Publicado: (2017)

Breeding Restrictions Decrease the Prevalence of Myxomatous Mitral Valve Disease in Cavalier King Charles Spaniels over an 8‐ to 10‐Year Period
por: Birkegård, A.C., et al.
Publicado: (2016)

Influence of concurrent lower respiratory tract disease on point‐of‐care lung ultrasound in small‐breed dogs with myxomatous mitral valve disease
por: Lam, Man‐Cham, et al.
Publicado: (2022)

Comparative effects of amlodipine and benazepril on Left Atrial Pressure in Dogs with experimentally-induced Mitral Valve Regurgitation
por: Suzuki, Shuji, et al.
Publicado: (2012)

Utility of Tissue Doppler Imaging in the Echocardiographic Evaluation of Left and Right Ventricular Function in Dogs with Myxomatous Mitral Valve Disease with or without Pulmonary Hypertension
por: Baron Toaldo, M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mfgvq65vpgil5e73pgv7gk311t